Sitemap - 2022 - The Microdose

$100 million for psychedelics: 5 Questions for philanthropist Blake Mycoskie

Will U.S. states legalize psychedelics by 2035? Company pledges not to sue Indigenous communities for violating patents, and Denver DA drops charges against “The Mushroom Rabbi.”

Holy bonding: 5 Questions for Episcopal priest Hunt Priest

Biological responses to ayahuasca, Portland store busted for openly selling illegal shrooms, and evaluating psychedelics’ abuse potential

From “just say no” to just say nothing: 5 Questions for harm reduction educator Rhana Hashemi

Bipartisan Breakthrough Therapies Act, NIMH lays out psychedelic research priorities, and grappling with a “bad trip”

Flickering lights and pseudo-hallucinations: 5 Questions for psychologist Reshanne Reeder

The case for interdisciplinarians: 5 Questions for psychologist Emily Bloesch

An Oregon training program folds, psychedelics in Congress, and trouble in Wonderland

Colorado and Oregon psychedelic ballot initiative updates, and don’t lick the toads

Athletes on psychedelics: 5 Questions for sports psychologist Courtney Walton

Colorado race heats up, Compass Phase 2b results, and Indigenous Ayahuasca Conference declaration

The purple politics of veterans and psychedelics: 5 Questions for Amber Capone, co-founder of VETS

We’re One! Lawyers appeal the DEA’s refusal to reschedule psilocybin, decrim in Australia, best practices for therapists, and psychedelics for schizophrenia

Who coined the term “psychedelic”? 5 questions for historian Erika Dyck

Banning Black women’s psychedelic Instagram accounts, the DEA’s 2023 psychedelic quotas, and why did fungi evolve psychedelic properties?

Reforming the patent system: 5 Questions for health justice lawyer Priti Krishtel

Alberta regulates psychedelic-assisted therapy, Phase 3 psilocybin clinical trials, LSD paper retracted, and what Biden’s marijuana pardons mean for psychedelics

Scientists synthesize non-hallucinogenic molecules chemically similar to psychedelics, another struggling psychedelic start-up, and mushroom tea bags

Psychedelic therapy and cancer: 5 Questions for oncologist Manish Agrawal

DEA charging thousands for Right To Try documents, a manifesto for psychonauts, and another one bites the dust

5 Questions for ibogaine researcher Thomas Kingsley Brown

Links between PTSD and hallucinogens, psychedelic investing beyond pharmaceuticals, and supporting survivors

Let old folks trip, patenting a psychedelic patch, and what do psychedelics and near-death experiences have in common?

Insurance coverage for psychedelics: 5 Questions for Enthea co-founder Sherry Rais

The psychedelic hype cycle, MindMed co-founder sues fellow co-founder, and patenting toad secretions

Psychedelics for alcoholism, another withdrawal from DEA, and Terran sues Compass

Oregon's Measure 109 opt-outs: 5 Questions for drug policy reform advocate Sam Chapman

Litigating the psychedelic renaissance: 5 Questions for attorney Matt Zorn

Capitalism and poetry: 5 Questions for psychedelics scholar Neşe Devenot

People’s expectations influence microdosing outcomes, Canadians sue government for psilocybin access, and a post-mortem on the DEA’s canceled tryptamine ban

"This is not Oregon": 5 Questions on California's decrim bill for state senator Scott Wiener

DEA abandons plan to prohibit more psychedelics, Colorado to vote on psychedelics in November, APA says science to support psychedelic treatment is “inadequate”

Why are we doing this? 5 Questions for doctor and MDMA researcher Sylver Quevedo

Psychedelic drugs for terminally ill patients, new federal bill includes additional psychedelics research funding, DEA faces FOIA suit

Culturally responsible care: 5 Questions for therapist Sara Reed

More Oregon counties want to ban psilocybin services, a review of microdosing, and remembering Ann Shulgin

Was Jesus a mushroom? 5 Questions on psychedelics and ancient religion with J. Christian Greer

Microdosing might boost mood and mental health, preparing for off-label use of psychedelics, and terminally ill patients likely to take DEA to court — again

Psilocybin initiative moves ahead in Colorado, COMPASS patent challenge, and psychedelics companies react to the fall of Roe v. Wade

5 Questions on measuring mental illness for psychology professor Eiko Fried

This Week in Psychedelics: “Candyflipping,” a non-hallucinogenic LSD, and reconsidering “treatment-resistant depression”

5 Questions for psychedelic professor Christine Ziemer

This Week in Psychedelics: Mail-order ketamine, a puzzling patent, and DMT under fluorescent lights

5 Questions for ayahuasca researcher Fernanda Palhano Xavier de Fontes

This Week in Psychedelics: Royalties for music used in psychedelic-assisted therapy, closed-door meeting in Oregon, and psilocybin in Jamaica

5 Questions for Reggie Harris

This Week in Psychedelics: Free LSD, Canadian government decriminalizes certain drugs in B.C., and psychedelic-assisted therapy

This Week in Psychedelics: Patenting psilocybin for cancer patients, crowdfunding for psychedelic brain science, and measuring psychedelic integration

5 Questions for Zac Kamenetz

This Week in Psychedelics: Senators push NIH and FDA on psychedelics, and will insurance pay for psychedelics?

This Week in Psychedelics: UK gets its first commercial clinical trial facility, 17 arrested at DEA protest, and critiquing the critique

5 Questions for Erinn Baldeschwiler

This Week in Psychedelics: Splashy results stoke criticism, Field Trip splits into two, and the half-truths in psychedelic marketing

5 Questions for Rebecca Kronman

This Week in Psychedelics: Inside a Vancouver shroom store, psychedelic chaplains, and Terran Biosciences’ new deals

5 Questions for Andrea Gomez

This Week in Psychedelics: Decriminalize Nature splinters, Bicycle Day, and an upcoming protest at the DEA

5 Questions for Rebecca Martinez

This Week in Psychedelics: Psilocybin changes brain connections, DEA to outlaw two more psychedelics, and is microdosing worth the risk?

5 Questions for Aaron Orsini

This Week in Psychedelics: Stock turmoil, Colorado bill withdrawn, and who can run a ketamine clinic

5 Questions for Joseph Holcomb Adams

This Week in Psychedelics: Shrooms for sale in British Columbia, disturbing MAPS MDMA trial footage released, and treating eating disorders with MDMA

5 Questions for Lynnette Averill

This Week in Psychedelics: New bills in Missouri and Rhode Island, drug interactions, and the trough of disillusionment

5 Questions for Mitchell Gomez

This Week in Psychedelics: Over 4,000 Oregonians weigh in on psilocybin therapy; health insurance for ketamine therapy; and abuses and shortcomings in “above-ground” psychedelic therapy

5 Questions for David Casimir

This Week in Psychedelics: Sustainable iboga, the Mushroom Rabbi, and trip setting

5 Questions for Gul Dolen

This Week in Psychedelics: Effects of psilocybin therapy a year later, Instagram removes psychedelics content, and the plight of the toads

5 Questions for David Bronner

This Week in Psychedelics: One shroom to rule them all, Canadian practitioners to be denied psilocybin access, and chronic pain relief

5 Questions for Shelby Hartman & Madison Margolin

This Week in Psychedelics: “Negligible” effects of microdosing, a DMT vape pen patent, and regulatory drama in Colorado and Maine

5 Questions for Carey Turnbull

This Week in Psychedelics: Psychedelics in the house, DEA moves to outlaw five tryptamines, and the future of psilocybin ads

5 Questions for Brandon Goode

This Week in Psychedelics: Hints of the future of legalized psilocybin in Oregon, new MDMA studies, and psychedelic polling

5 Questions for Kristin Nash

This Week in Psychedelics: Health Canada streamlines psychedelic treatment request system, NIH’s psychedelic Zoom, virtual reality, and hallucinogens in ancient Peruvian politics

5 Questions for Robin Carhart-Harris

This Week In Psychedelics: The science behind FTO’s Compass patent challenges, living with HPPD, big pharma invests in psychedelics, and more

5 Questions for Lily Kay Ross